BRANFORD, Conn.--(BUSINESS WIRE)--454 Life Sciences, a Roche Company (SWX:RO)(SWX:ROG)(Pink Sheets:RHHBY), announced today the launch and immediate availability of the new GS FLX+ System, an instrument capable of generating extra-long sequencing reads up to 1,000 by in length. This new level of performance presents a major milestone in the life science’s industry, making it the first high-throughput sequencing technology to deliver millions of bases from reads with accuracy and lengths that are comparable to Sanger-based methods. The improvements in read length also translate to a 50% increase in total throughput, aiding in overall run economics and further reducing the cost of large genomic projects.
